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Abstract: In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example
for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC
lacking targetable genetic alterations, immune checkpoint inhibition (ICI) has become standard of care
in first-line treatment or beyond. PD-L1 tumor expression represents the only approved predictive
biomarker for PD-L1/PD-1 checkpoint inhibition by therapeutic antibodies. Since PD-L1-negative or
low-expressing tumors may also respond to ICI, additional factors are likely to contribute in addition
to PD-L1 expression. Tumor mutation burden (TMB) has emerged as a potential candidate; however,
it is the most complex biomarker so far and might represent a challenge for routine diagnostics.
We therefore established a hybrid capture (HC) next-generation sequencing (NGS) assay that covers
all oncogenic driver alterations as well as TMB and validated TMB values by correlation with the assay
(F1CDx) used for the CheckMate 227 study. Results of the first consecutive 417 patients analyzed
in a routine clinical setting are presented. Data show that fast reliable comprehensive diagnostics
including TMB and targetable alterations are obtained with a short turn-around time. Thus, even
complex biomarkers can easily be implemented in routine practice to optimize treatment decisions
for advanced NSCLC.
Cancers 2020, 12, 1685; doi:10.3390/cancers12061685 www.mdpi.com/journal/cancers
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1. Introduction
In advanced non-small cell lung cancer, immune checkpoint inhibitors (ICIs) targeting
the PD-1/PD-L1 axis, have sustainably changed the therapeutic approach of driver mutation
negative tumors. ICIs have become available for first- and second-line treatment and represents
a next step in the effort to reduce the group of patients receiving systemic chemotherapy.
Despite these advances, a limited group of about 20% of NSCLC patients still benefit from ICI.
Biomarkers are needed to predict the response outcome before initiation of therapy. As of now, PD-L1
expression has been established as the only predictive biomarker for treatment with ICIs; nevertheless,
several factors are limiting its predictive value. Firstly, tumor heterogeneity in terms of PD-L1 tumor
expression can be significant and can also change in response to therapy. Secondly, PD-L1-negative
tumors have been reported to respond to ICI as well, rendering PD-L1 an imperfect biomarker and
urging the need for other biomarkers, such as microsatellite instability (MSI) and TMB [1–7]. Potentially,
TMB may be an independent factor from PD-L1 expression in predicting outcome. TMB is referred to
as the total number of somatic mutations that occur in an exome of a tumor genome, although the
exact calculation and definition of TMB might differ based on the type of variants, region size,
or localization [8,9]. Exonic mutations can lead to the translation of novel peptide epitopes on the
tumor surface that may increase the immunogenicity and, therefore, trigger an immune response [9–13].
TMB has been demonstrated to be a strong predictive value for the efficacy of ICI in second- and third-line
monotherapy, in first-line monotherapy, and in the first-line combination of immuno-oncological (IO)
substances, even if the patients’ tumors did not show expression of PD-L1 [14–17]. Furthermore,
TMB is evaluated for the selection of patients who benefit from the combination of nivolumab
and ipilimumab over platinum-based chemotherapy [18]. A recent study described TMB as a
predictor for survival after immunotherapy across multiple cancer types, including head and neck,
bladder, breast, and renal cancer, underlining the general validity of TMB stratification [19]. Two
other recent studies revealed that the efficacy of pembrolizumab plus chemotherapy or placebo plus
chemotherapy as first-line treatment was not associated with TMB [20,21]. The lack of correlation
between PD-L1-expression and TMB status has been observed in several different studies, highlighting
the independent and potential complementary role for both biomarkers [14–16,22]. However, the
measurement and calculation of TMB still misses uniform standards. Several factors can influence
TMB, including the DNA repair capacity and mutation rate. Because current neoantigen-predictive
algorithms are imperfect, it is likely that the relationship between TMB and antigenicity is complex.
Furthermore, additional factors can affect immunogenicity, including the clonality of neoantigens and
the tumor microenvironment [9]. In addition, tumor heterogeneity and clonal architecture, the size
of the selected genomic region of interest, and setup regarding driver mutational panel bias or even
tumor purity can also influence the results from a biological perspective. From the technical point
of view, NGS-derived deamination artifacts, the lack of predefined cut-off values; and the mutation
types challenge the introduction of TMB as a general biomarker for immunotherapies [23]. The clinical
utility of TMB is also affected by pre- and postanalytic parameters, such as storage of the formalin fixed
paraffin embedded (FFPE) sample, turn-around time (TAT), or analysis failure rate [24,25]. To evaluate
the importance of TMB as a practical biomarker, clinical routine data are needed. Here, we present the
first TMB mono-centric dataset from a cohort of 417 lung cancer samples in Germany. We aimed to
cover the proposed gaps by discussing clinical usability as driver mutations and TMB in the period
from 2018 to 2020 using a commercially available assay (NEOplus v2 RUO‡, NEO New Oncology
GmbH). The assay was designed to detect targetable driver mutations and genomic alterations (i.e.,
translocations, copy number changes) of other clinically relevant genes, such KRAS, KEAP1, STK11,
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and ARIDA1 (Appendix A), as well as to estimate TMB in an exonic territory of 1.14 Mb. After internal
validation, the assay was used in our accredited clinical laboratory for routine mutation analysis
in NSCLC patients. Samples were exclusively tested upon request by the attending physician and
therefore reflect real world data
2. Results
2.1. TMB Assay Correlation with Clinical Trail Assay of CheckMate 227
To determine whether the assay was able to estimate TMB comparable to the assay used in the
CheckMate 227 clinical trial, a series of 17 samples were analyzed both in-house as well as by F1CDx
(Foundation Medicine Inc., Cambridge Massachusetts)
A high correlation (R2 = 0.884, 95% CI [0.799, 0.968]) between both assays was observed and the
TMB category (high vs. low) showed 80% (12/15) concordance with the F1CDx category with a cut-off
of 10 mut/Mb (Figure 1).
Figure 1. Correlation of TMB estimation of 17 samples measured by NEOplus v2 RUO‡ and
F1CDx assays.
2.2. Histology, Driver Mutations, and PD-L1
In this cohort, 42.4% (177/417) of patients were of female gender and 57.6% (240/417) were
male, the mean age being 66 years (Table 1). Histological classification revealed 73.9% (308/417)
adeno carcinomas, 0.2% (1/417) adeno-squamous, 7.9% (33/417) squamous cell, 1.0% (4/417) small cell
lung cancer, 0.5% (2/417) of cases displayed large cell neuroendocrine differentiation, while 16.5%
(69/417) were not otherwise specified (NOS). EGFR mutations were detected with a frequency of
14.87% (62/417); however, only 66% (41/62) constituted the classical targetable drivers including exon
19 deletions or L858R. The remaining 34% were mostly located outside exons 18–21. Exon 20 insertions,
resistant to first-, second-, and third-generation EGFR tyrosine kinase inhibitors (TKIs), were detectable
in six cases (6/417, 1.4%) (Table 1).
Several point mutations were detected within the BRAF gene (36/417, 8.63%); among these,
nine were BRAF V600E. Deemed targetable gene fusions were found with a frequency of 9.83% (41/417),
including 15 (3.66%) EML4-ALK, 2 CD74-ROS1 (0.48%), and 3 RET translocations (0.73%, 2x KIF5B-RET,
RET-CCDC6). Several other fusions were detected, including inter- and intragenic fusions of TP53,
RB1, STK11, and CDKN2A/B. Within the group of adenocarcinomas, 79.9% of cases were devoid of a
targetable driver alteration and 1.6% showed wildtype in all 39 therapeutically relevant genes. None of
the squamous cell carcinomas showed a targetable driver alteration. In parallel to mutational analysis,
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PD-L1 immunohistochemistry (IHC) was performed and the tumor proportion score (TPS) was
determined for each sample. In total, 123/417 (29.5%) of tumors did not express PD-L1 (<1% of PD-L1),
while 11.99% showed PD-L1 expression between ≥1% and <5% PD-L1, 18.94% between ≥5% and
<50% PD-L1, and 23.74% of cases had strong PD-L1 expression (≥50% PD-L1). In 15.8% of cases,
no PD-L1 analysis was performed either because it was not requested by the physician or due to
limited tissue availability.
Table 1. Overview of patients’ characteristics according to TMB values.
Variation
Total TMB < 10 TMB > 10
N = 417 N = 260 (62.35%) N = 157 (37.65%)
Age
Median 66 66 66
Mean (±SD) 65.0 (11.8) 64.7 (12.5) 65.7 (10.5)
Range 21–92 21–92 93–90
<65 years 199 (47.72%) 126 (48.46%) 73 (46.50%)
≥65 years 218 (52.28%) 134 (51.54%) 84 (53.50%)
Sex
Female 177 (42.45%) 140 (53.85%) 100 (63.69%)
Male 240 (57.55%) 120 (46.15%) 57 (36.31%)
Histology
Adenocarcinoma 308 (73.86%) 201 (77.31%) 107 (68.15%)
Squamous 33 (7.91%) 14 (5.38%) 19 (12.10%)
Adeno-squamous 1 (0.24%) 1 (0.38%)
Large-cell
neuroendocrine 2 (0.48%) 2 (1.27%)
SCLC 4 (0.96%) 4 (1.54%)
NOS 69 (16.55%) 40 (15.38%) 29 (18.47%)
EGFR Status
Mutant 62 (14.87%) 47 (18.08%) 15 (9.55%)
Wild type 355 (85.13%) 213 (81.92%) 142 (90.45%)
targetable EGFR




3 (4.84%) 3 (1.15%)
EGFR exon 20 insertion 6 (9.68%) 6 (2.31%)
other / variant of
unknown significance 12 (19.35%) 5 (1.92%) 7 (4.46%)
BRAF Status
Mutant 36 (8.63%) 20 (7.69%) 16 (10.19%)
Wild type 381 (91.37%) 240 (92.31%) 141 (89.81%)
V600E / class I * 9 (25.00%) 8 (3.08%) 1 (0.64%)
non-V600E / class II * 11 (30.56%) 5 (1.92%) 6 (3.82%)
non-V600E / class III * 5 (13.89%) 3 (1.15%) 2 (1.27%)
other mutation / variant
of unknown
significance
11 (30.56%) 4 (1.54%) 7 (4.46%)
Gene Fusions
Mutant 41 (9.83%) 32 (12.31%) 9 (5.73%)
Wild type 368 (88.25%) 223 (85.77%) 145 (92.36%)
n.d. 8 (1.92%) 5 (1.92%) 3 (1.91%)
ALK translocation 15 (36.59%) 14 (5.38%) 1 (0.64%)
ROS1 translocation 2 (4.88%) 1 (0.38%) 1 (0.64%)




21 (51.22%) 14 (5.38%) 7 (4.46%)
PD-L1 TPS
<1% 123 (29.50%) 79 (30.38%) 44 (28.03%)
≥1% and <5% 50 (11.99%) 26 (10.00%) 24 (15.29%)
≥5% and <50% 79 (18.94%) 55 (21.15%) 24 (15.29%)
≥50% 99 (23.74%) 53 (20.38%) 46 (29.30%)
n.d. 66 (15.83%) 47 (18.08%) 19 (12.10%)
* BRAF mutations were classified based on Yao et al. [26].
2.3. Turn-Around Time and HC NGS Workflow
According to European guidelines, turn-around times for molecular testing in advanced lung
cancer should take no longer than 10 working days [27,28]. We initially wanted to determine whether
comprehensive testing including TMB estimation was feasible within this timeframe. To that end,
we analyzed the first 115 cases for turn-around time and found that from 81.7% (94/115) of cases a
result was sent to the treating physician within 10 working days (Figure 2). To further improve on the
turn-around time, we looked at the steps responsible for possible delays more closely. The HC NGS
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workflow was subdivided into library preparation, sequencing, bioinformatics (data processing),
and generation of a pathological report. Underlying causes for extended turn-around times
in these 21 cases were delays in reporting (33%) mainly due to complex genomic alterations;
library preparation (38%), such as insufficient DNA at intermediate steps of library preparation requiring
some step to be repeated; other technical issues (19%), such as operator or handling mistakes; or delays
in data handling and bioinformatics due to server drop out (10%) (Figure 2). Pre-analytics, including
FFPE embedding, histological evaluation for tumor content and DNA extraction, required between 2
to 5 days in 80% of cases. More than 5 days were needed in 20% of samples due to delays in workflow
(Figure 2). As only one HC NGS run was performed initially per week, the sample entry date also
influenced overall TAT.
Figure 2. Turn-around time for TMB evaluation. (A) TAT in working days per case from start of HC NGS
workflow to reporting; (B) Duration of pre-analytics including tissue embedding and DNA extraction;
(C) Reasons for prolonged TAT (>10 working days); (D) Percentage of cases not meeting quality criteria.
2.4. Evaluation of Tumor Mutation Analysis in Routine Lab Samples
2.4.1. TMB in Relation to Age
Based on these findings, we considered the assay set up sufficiently fast to continue using the
assay for further routine diagnostics including targetable mutations. After a total of 417 were analyzed,
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we correlated patient-specific parameters with the observed TMB values. There appeared no significant
age- (p= 0.476) or gender (p = 0.110)-specific association with TMB (Figure 3).
Figure 3. TMB status (mut/Mb) is not significantly correlated to age or gender. Boxplots are shown
with the 95% confidence interval indicated by the box. Lines indicate the mean and + the median.
Statistical analysis by Student t test did not reveal significant differences in TMB between patients
under or over 65 years of age (p = 0.476), nor between male and female patients (p = 0.110).
2.4.2. TMB in Relation to Driver Mutations
Recent reports suggest that the presence of typical driver alterations inversely correlates with the
number of somatic tumor mutations [29,30]. In our cohort, targetable driver alterations (EGFR, ALK,
ROS, BRAF V600E, RET) occurred at a combined frequency of 17.5% (73/417). The majority of this
group of patients 62/73 (84.9%) showed a lower TMB, below a cut-off of 10 mut/Mb, while only 11/73
(15.1%) patients were in the TMB-high group (≥10mut/Mb).
The most prevalent somatic mutations found were TP53 (237/417, 56.8%), followed by KRAS
(135/417, 32.4%), KEAP1 (54/417, 15.8%), STK11 (64/417, 15.3%), EGFR (62/417, 14.9%), ATM (46/417,
11.03%), and others. Gene amplifications were discovered in 45/417 (10.8%) and gene fusions in 9.83%
(41/417) of cases (Figure 4).
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Figure 4. Number of tumors carrying non-synonymous gene mutations in descending order of
frequency (grey), including gene amplifications, fusions, and deletions (blue).
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2.4.3. TMB and PD-L1
Data from the literature indicate that PD-L1 expression on tumor cells does not correlate with
TMB and that TMB should therefore be considered as an independent predictive biomarker [31]. In line
with this observation, we found no significant association between the TMB value and PD-L1 TPS
(Figure 5). Further, we categorized the tumors on the basis of PD-L1 tumor proportion scores and
observed no statistically significant association (as assessed by analysis of variance, ANOVA) of PD-L1
tumor expression and TPS scores (p = 0.798).
Figure 5. TMB is not different in the four groups of the PD-L1 tumor proportion score. Data are
presented as box plots with a 95% confident interval. The line indicates the mean, the + indicates the
median. Statistical analysis by ANOVA did not reveal significant (p < 0.05) differences in TMB between
TPS groups.
2.4.4. Correlation of Somatic Tumor Mutations and TMB
It has been shown that the presence of targetable driving mutations, such as activating
EGFR mutations, is associated only with limited responses to immune checkpoint inhibitors [32].
It has been postulated that this is due to low TMB. Particularly, EGFR and ALK mutations are more
frequent in light or never smokers, further supporting this hypothesis [33]. Tumors characterized by
a targetable driver alteration show significantly lower TMB compared to those lacking any driver
alteration (p < 0.001). TMB in EGFR mutated tumors was significantly lower compared to TMB
in KEAP1 (p < 0.01), ARID1A (p < 0.05), STK11 (p < 0.05), and POLE (p < 0.05) mutated tumors.
Along those lines, TMB in ALK mutated tumors was significantly lower compared to KEAP1, ARID1A,
POLE, and STK11 mutated tumors (each p <0.05) (see Figure 6).
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Figure 6. TMB and clinically relevant genetic alterations. For targetable driver alterations
(green and blue), TKI-sensitive mutations were counted. Regarding KEAP1, ARID1A, STK11, and POLE,
all non-synonymous aberrations (red) were considered. Data are presented as box plots with a 95%
confident interval. The line indicates the mean, the + indicates the median. Statistical analysis by
ANOVA revealed significant differences in TMB between EGFR and KEAP1, ARID1A, POLE, and STK11
(#) mutated groups; between ALK fusion and KEAP1, ARID1A, POLE, and STK11 mutated groups (§);
and between targetable driver mutations and all red groups (¶); and lastly, between targetable and
non-targetable driver mutation groups (¶¶).
2.5. Clinical Use of IO-Related Biomarkers in Clinical Decision-Making
Recent publications suggest that STK11 and KEAP1 mutations might be associated with an inferior
response to IO [34,35]. Contrarily, ARID1A mutations seem to confer positive prediction [36]. Based on
these findings, we observe that clinicians are interested in additional biomarkers with predictive value
for IO.
Inactivating mutations in STK11 were detected with a frequency of 11.3% (47/417) and for
KEAP1 with 7.7% (32/417). Functional mutations in ARID1A were found in 5.3% (22/417) of patients.
Interestingly, all these variants were associated with higher TMB values, indicating that particularly
STK11 and KEAP1 are biomarkers independent from TMB.
3. Discussion
When TMB emerged as a potential predictive biomarker, it was considered to possibly be the
most challenging and complex genomic biomarker to date. NGS-based sequencing of a minimum
of one Megabase exonic territory in combination with advanced bioinformatics analyses is needed.
The NEOplus v2 RUO‡ panel has a total territory of 2.50 Mb, of which 1.14 Mb are dedicated to
TMB evaluation. The territory dedicated to TMB evaluation excludes typical cancer genes that are
known to have a mutation bias. The need for a TMB territory size of greater than 1 Mb is based on the
data of Chalmers et al. and generally considered to be sufficient. This is supported by the comparisons
of several TMB assays in the recently published German comparative TMB study [37]. There was
considerable doubt whether speedy local TMB testing could be implemented and whether testing
large number of patients was feasible. The initiatives of Quality in Pathology and Friends of Cancer
Research jointly addressed the need for harmonization of TMB testing. In this study on a cohort of
417 lung cancer patients, we asked whether TMB can be assessed alongside other predictive genomic
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biomarkers needed for treatment stratification. We implemented an HC NGS assay into routine
diagnostics, allowing for simultaneous detection of TMB and relevant aberrations including targetable
driver mutations. TMB values correlated well with the F1Dx panel. These data are compatible with
previously published data from a German harmonization trial [24,37].
The TAT proved to be in line with guidelines as 81.7% of cases met the required turn-around
time of 10 working days. Comparing the NEOplus v2 RUO‡ HC assay to the F1Dx assay (used in
CheckMate 227) revealed a high degree of association.
Samples analyzed in this study mainly consisted of adenocarcinomas; however, a significant
proportion of biopsies were histologically classified in external pathologies and the histological subtype
was not reported to us. Therefore, a relatively large proportion appeared as NOS; unfortunately,
in most cases, tissue was not sufficient for reevaluation. TMB was not associated to age in our cohort,
although previously, an age effect was published regarding other cancer entities [38]. TMB and
PD-L1 expression was not associated, supporting the concept of two independent and therefore
potentially additive biomarkers for immune oncological treatment. Male gender appears to be
associated with higher TMB compared to females, potentially reflecting different smoking habits;
however, this difference was not statistically significant. The frequency of targetable driver alterations
(EGFR, ALK, ROS1, MET exon 14 skipping, RET, or BRAF V600E) was in line with the literature and
their presence was significantly associated with a lower TMB value. In contrast, tumors that carried
mutations in KRAS or genes assumed to cause primary resistance to IO (STK11, KEAP1, and POLE)
showed higher TMB. In 2019, the complex CheckMate 227 trial using TMB as a co-primary endpoint in
some subgroups could not convincingly show a role for TMB as a useful predictive biomarker. Since
then retrospective analyses explored the use of pembrolizumab versus chemotherapy in all therapeutic
lines, showing improvement in OS, PFS, and ORR for TMB-high patients [39,40].
Based on the KEYNOTE-158 trial, the FDA recently approved pembrolizumab monotherapy for
patients with solid tumors and TMB≥10 mut/Mb. The study included adults and pediatric patients with
unresectable or metastatic disease with progression upon prior treatment or no alternative treatment
options. This underlines the concept of TMB as a predictive biomarker [41].
4. Materials and Methods
4.1. Selection of Patients
Patients were retrospectively selected from our internal pathological documentation system based
on the request for comprehensive molecular testing from 2018 to 2019. All samples represent tumor
biopsies tested in a single institution (Institut für Hämatopathologie Hamburg, Germany). Use of
anonymized patient data was reviewed by the local ethics committee (Ref number: WF-055/18 and
WF-017/19.)
4.2. PD-L1
PD-L1 was stained immunohistochemically using the antibody clone 22C3 pharm Dx (Dako Omnis,
1:30 dilution) on the automated BenchMark Ultra platform (Roche Diagnostics) with positive controls
of the spleen, tonsil, and placenta as part of a multi-tissue control. Scoring was conducted by
board-certified and trained pathologists [42].
4.3. Mutation Testing
For molecular analysis, 3–10 5–10µm micrometer formalin-fixed paraffin-embedded (FFPE)
sections were prepared and tumor tissue was micro-dissected when the tumor content was
below 10%. DNA was extracted semi-automated (Maxwell®16, Promega), and 400ng of input
DNA was sonographically sheared (Covaris®) into approximately 200-bp double-stranded fragments.
Hereafter, adapters were ligated, and genomic regions of interest were enriched using complementary
bait sequences. During this hybrid capture, the selected baits ensure optimal coverage of all relevant
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genomic regions, including 340 genes in a 1.14 Mb complete genomic territory size. Following the
enrichment, the targeted fragments were clonally amplified and sequenced with next-generation
sequencing (NextSeq 500/550, Illumina). Point mutations, small insertions and deletions, copy number
alterations, and rearrangement/gene fusions were identified with NEO New Oncology’s proprietary
computational biology analysis pipeline and analyzed using the NEO diagnosis software.
4.4. TMB
For TMB, the number of somatic mutations detected within 1.14 Mb of the genome were quantified
and that value extrapolated to the whole exome using a validated algorithm (NEO New Oncology).
Alterations known to be included in genomic databases, such as Single Nucleotide Polymorphism
Database (dbSNP) or Exome Aggregation Consortium (ExAc), were excluded.
TMB was calculated from genomic alterations identified by the bioinformatics pipeline.
Single nucleotide changes with predicted missense, nonsense, silent, nonstop consequences, and small
insertions/deletions with in-frame or frameshift insertion/deletion consequences were considered
for TMB calculation. Variants with an allelic frequency of at least 5% (for LOD 0.05 value) or 10%
(for LOD 0.1 value) were included and frequent germ line variants present in ExAc and dbSNP were
not considered. The TMB value was provided as mutations per Megabase (mut/Mb).
4.5. Statistical Analysis
Descriptive statistics were used. Differences between groups were tested with parametric or
non-parametric methods depending on the distribution. Box plots were generated using GraphPad
Prism 7.04 (GraphPad Software, Inc., San Diego, CA) and statistical significance assessed by Student t
and ANOVA (Alpha level 0.05). For Figure 1, Pearson correlation was performed using Microsoft Excel.
5. Conclusions
We showed that routine diagnostics of highly complex biomarkers, such as TMB, is feasible today
and that a central industrial testing facility is not required. This is a highly important finding given
that clinical trial results using TMB as a predictive biomarker are promising and FDA approval is
currently pending. However, at this point in time, data are still not fully mature and further validation
is required.
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Appendix A
List of genes included in NEOplus v2 RUO‡. NEOplus v2 RUO‡ detects point mutations in
330 genes and small insertions and deletions in 325 genes, as well as copy number changes in 230 genes.
In addition, gene fusions are detected in 16 genes.
‡ For Research Use Only. Not for use in diagnostic procedures.
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Point Mutations, small Insertions and Deletions
ABL1, ABL2, ACVR1B, AKT1, AKT2, AKT3, ALK, ALMS1, AMER1, APC, APLNR, AR, ARAF,
ARHGEF12, ARID1A, ARID1B, ARID2, ASXL1, ATAD5*, ATM, ATR, ATRX, AURKA, AURKB, AXIN2,
AXL, B2M, BAP1, BARD1, BCL2, BCL2L1, BCL6, BLM, BMPR1A, BMS1, BRAF, BRCA1, BRCA2,
BRD2, BRD3, BRD4, BRIP1, BTK, BUB1B, CARD11, CASP8, CBFB, CBL, CCND1, CCND2, CCNE1,
CD274, CD58, CD79A, CD79B, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN1A, CDKN1B,
CDKN2A, CDKN2B, CDKN2C, CEBPA, CHD4, CHEK1, CHEK2, CIC, CLSPN, CREBBP, CRKL, CSF1R,
CTCF, CTNNA1, CTNNB1, CUL3, DAXX, DCUN1D4, DDB2, DDR2, DICER1, DOT1L, EGFR, EMSY,
EP300, EPHA3, EPHA5, EPHA7, EPHB1, ERBB2, ERBB3, ERBB4, ERCC3, ERCC4, ERCC5, ERCC6,
ERRFI1, ESR1, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL,
FANCM, FAS, FAT1, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLCN, FLT1, FLT3, FOXO3, FOXP1,
FRS2, GATA1, GEN1, GLI1, GNA11, GNA13, GNAI2, GNAQ, GNAS, GNAT2, GSK3B, H3F3A, H3F3B,
HDAC2, HGF, HLTF, HRAS, HSP90AA1, IDH1, IDH2, IFNGR1, IFNGR2, IGF1R, IGF2, IGF2R, IKBKB,
IKBKE, IL21R, INHBA, INPP4B, IRF1, IRF2, IRF4, JAK1, JAK2, JAK3, JUN, KAT6A*, KDR, KEAP1,
KIT, KMT2A, KMT2B, KMT2C, KMT2D, KRAS, KSR1, LRP1B, LYN, MAD2L1, MAGI2, MAP2K1,
MAP2K3, MAP2K4, MAP3K1, MCL1, MDM2, MDM4, MED12, MEN1, MET, MITF, MLANA, MLH1,
MLH3, MPL, MRE11, MSH2, MSH3, MSH5, MSH6, MST1R, MTOR, MUTYH, MYC, MYCL, MYCN,
NBN, NCOA3, NCOA4, NF1, NF2, NFE2L2, NFKBIA, NOTCH2, NOTCH4, NPM1, NRAS, NSD1,
NTRK1, NTRK2, NTRK3, PALB2, PBRM1, PDCD1LG2, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3CA,
PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PLCG2, PMS2, POLD1, POLE, POLG, POLH, POT1,
PPM1D, PPP2R1A, PRDM1, PREX2, PRKCI, PRKDC, PRKN, PSMB5, PTCH1, PTEN, PTPN11, PTPRC,
PTPRK, PTPRT, QKI, RAC1, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RAD54L2, RAF1,
RANBP2, RARA, RB1, RECQL4, RET, REV3L, RICTOR, RIT1, RNF43, RNPS1, ROS1, RPL10A, RPL23,
RPTOR, SDHA*, SDHAF2, SDHB, SDHC, SDHD, SERPINB3, SERPINB4, SETD1A*, SETD1B, SETD2,
SF3B1, SLIT2, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMARCB1, SMO, SOX2, SPEN, SPOP,
SRP54, STAG2, STAT3, STK11, SUFU, SYK, TAF3, TAP1, TAP2, TAPBP, TCF7L2, TGFBR2, TNFAIP3,
TNFRSF14, TOP1, TOP2A, TP53, TP53BP1, TRRAP, TSC1, TSC2, TSHR, U2AF1, U2AF1L5, VEGFA,
VHL, WISP3, WRN, WT1, XPA, XPC, XRCC1, ZFHX3*, ZNF217
* Detection of small insertions and deletions in ATAD5, KAT6A, SDHA, SETD1A, ZFHX3
not possible.
Copy Number Changes
ABL1, AKT1, AKT2, AKT3, ALK, ALMS1, AMER1, APC, APLNR, AR, ARAF, ARID1A, ARID1B,
ARID2, ASXL1, ATAD5, ATM, ATR, ATRX, AURKA, AXIN2, AXL, BARD1, BCL6, BLM, BMPR1A,
BMS1, BRAF, BRCA1, BRCA2, BRD2, BRD3, BRD4, BRIP1, BTK, BUB1B, CARD11, CASP8, CCND1,
CCNE1, CD274, CDC73, CDH1, CDK12, CDK4, CDK6, CDK8, CDKN2A, CDKN2B, CHD4, CIC,
CLSPN, CREBBP, CSF1R, CTNNA1, CTNNB1, CUL3, DAXX, DDB2, DDR2, DICER1, DOT1L, EGFR,
EMSY, EP300, EPHA3, EPHB1, ERBB2, ERBB3, ERBB4, ERCC3, ERCC4, ERCC5, ERCC6, ERRFI1, ESR1,
EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCI, FANCL, FANCM, FAS, FAT1, FGF19$,
FGF23#, FGF3$, FGF4$, FGF6#, FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT3, FOXO3, FOXP1, FRS2,
GATA1, GLI1, GSK3B, HDAC2, IDH1, IDH2, IFNGR1, IKBKB, IKBKE, IL21R, INHBA, INPP4B, IRF1,
IRF2, IRF4, JAK1, JAK2, JAK3, KAT6A, KDR, KEAP1, KIT, KRAS, LRP1B, LYN, MAGI2, MAP2K1,
MDM2, MDM4, MED12, MEN1, MET, MITF, MLH1, MPL, MRE11, MSH2, MSH3, MSH5, MSH6,
MST1R, MUTYH, MYC, MYCL, MYCN, NBN, NCOA3, NCOA4, NF1, NF2, NFE2L2, NPM1, NSD1,
NTRK1, NTRK2, NTRK3, PALB2, PBRM1, PDGFRA, PDGFRB, PDK1, PIK3C2B, PIK3CA, PIK3CB,
PIK3CD, PIK3CG, PIK3R1, PIK3R2, PMS2, POLD1, POLE, POLG, POLH, PPM1D, PRDM1, PTCH1,
PTEN, PTPN11, PTPRK, QKI, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L, RAD54L2,
RAF1, RANBP2, RARA, RB1, REV3L, RICTOR, RIT1, RNF43, ROS1, RPTOR, SETD1A, SETD1B, SETD2,
SF3B1, SLIT2, SLX4, SMAD2, SMAD3, SMAD4, SMARCA4, SMO, SPOP, STAG2, STAT3, STK11, SYK,
TAP1, TAP2, TAPBP, TGFBR2, TNFAIP3, TOP1, TOP2A, TP53, TP53BP1, TRRAP, TSC1, TSC2, VEGFA,
WRN, XPC, XRCC1
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$ genes considered as one cluster
# genes considered as one cluster
Gene Fusions
ALK, BRAF, CD74, EML4, ETV6 (NTRK3 Fusion), FGFR1, FGFR2, FGFR3, KIF5B, MET, NRG1,
NTRK1, PDGFRA, RET, ROS1
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